R J Schmidt1, C Baylis. 1. Departments of Medicine and Physiology, West Virginia University School of Medicine, Morgantown 26506, USA. rschmid@wvu.edu
Abstract
BACKGROUND: A deficiency of the endogenous vasodilator nitric oxide (NO) has been implicated as a potential cause of hypertension in chronic renal disease (CRD) patients. This study was conducted to determine whether 24-hour NOX (NO2 and NO3) excretion (a qualitative index of total NO production) is reduced in patients with CRD. METHODS: Measurements were made in 13 CRD patients and 9 normotensive healthy controls after 48 hours on a controlled low-NOX diet. Urine was collected over the second 24-hour period for analysis of 24-hour NOX, and cGMP and blood drawn at the completion. Plasma levels of arginine (the substrate for endogenous renal NO synthesis), citrulline (substrate for renal arginine synthesis), and the endogenous NO synthesis inhibitor asymmetrical dimethylarginine (ADMA) and its inert isomer and symmetrical dimethylarginine (SDMA) were also determined. RESULTS: Systolic blood pressure was higher in CRD patients (12 of whom were already on antihypertensive therapy) than in controls (P < 0.05). Twenty-four-hour urinary NOX excretion was low in CRD patients compared with controls despite similar dietary NO intake, suggesting that net endogenous NO production is decreased in renal disease. In contrast, the 24-hour urinary cGMP did not correlate with UNOXV. Plasma citrulline was increased in CRD patients, possibly reflecting reduced conversion of citrulline to arginine. Plasma arginine was not different, and plasma ADMA levels were elevated in CRD versus controls, changes that would tend to lower NO synthase. CONCLUSION: These results suggest that NO production is low in CRD patients and may contribute to hypertension and disease progression in CRD.
BACKGROUND: A deficiency of the endogenous vasodilator nitric oxide (NO) has been implicated as a potential cause of hypertension in chronic renal disease (CRD) patients. This study was conducted to determine whether 24-hour NOX (NO2 and NO3) excretion (a qualitative index of total NO production) is reduced in patients with CRD. METHODS: Measurements were made in 13 CRDpatients and 9 normotensive healthy controls after 48 hours on a controlled low-NOX diet. Urine was collected over the second 24-hour period for analysis of 24-hour NOX, and cGMP and blood drawn at the completion. Plasma levels of arginine (the substrate for endogenous renal NO synthesis), citrulline (substrate for renal arginine synthesis), and the endogenous NO synthesis inhibitor asymmetrical dimethylarginine (ADMA) and its inert isomer and symmetrical dimethylarginine (SDMA) were also determined. RESULTS: Systolic blood pressure was higher in CRDpatients (12 of whom were already on antihypertensive therapy) than in controls (P < 0.05). Twenty-four-hour urinary NOX excretion was low in CRDpatients compared with controls despite similar dietary NO intake, suggesting that net endogenous NO production is decreased in renal disease. In contrast, the 24-hour urinary cGMP did not correlate with UNOXV. Plasma citrulline was increased in CRDpatients, possibly reflecting reduced conversion of citrulline to arginine. Plasma arginine was not different, and plasma ADMA levels were elevated in CRD versus controls, changes that would tend to lower NO synthase. CONCLUSION: These results suggest that NO production is low in CRDpatients and may contribute to hypertension and disease progression in CRD.
Authors: R J Schmidt; J Domico; L S Samsell; S Yokota; T S Tracy; M I Sorkin; K Engels; C Baylis Journal: Am J Kidney Dis Date: 1999-08 Impact factor: 8.860
Authors: R Wever; P Boer; M Hijmering; E Stroes; M Verhaar; J Kastelein; K Versluis; F Lagerwerf; H van Rijn; H Koomans; T Rabelink Journal: Arterioscler Thromb Vasc Biol Date: 1999-05 Impact factor: 8.311
Authors: J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich Journal: J Am Soc Nephrol Date: 1999-03 Impact factor: 10.121
Authors: M Blum; T Yachnin; Y Wollman; T Chernihovsky; G Peer; I Grosskopf; E Kaplan; D Silverberg; S Cabili; A Iaina Journal: Nephron Date: 1998 Impact factor: 2.847
Authors: Deborah L Feairheller; Kathleen M Sturgeon; Keith M Diaz; Praveen Veerabhadrappa; Sheara T Williamson; Deborah L Crabbe; Michael D Brown Journal: Kidney Blood Press Res Date: 2010-07-13 Impact factor: 2.687
Authors: Christopher D Owens; Nicole Wake; Ji Min Kim; Dirk Hentschel; Michael S Conte; Andres Schanzer Journal: J Vasc Access Date: 2010 Oct-Dec Impact factor: 2.283
Authors: Stephen L Seliger; Leslie I Katzel; Jeffrey C Fink; Matthew R Weir; Shari R Waldstein Journal: Am J Nephrol Date: 2007-11-16 Impact factor: 3.754
Authors: Jennifer C Sullivan; Jennifer L Pardieck; Kelly A Hyndman; Jennifer S Pollock Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-11-04 Impact factor: 3.619
Authors: Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson Journal: J Am Soc Nephrol Date: 2016-09-12 Impact factor: 10.121